| Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota A Cebula, M Seweryn, GA Rempala, SS Pabla, RA McIndoe, TL Denning, ... Nature 497 (7448), 258-262, 2013 | 423 | 2013 |
| Mutation-Derived Neoantigens for Cancer Immunotherapy RBSJSB John C. Castle, Mohamed Uduman, Simarjot Pabla Frontiers in immunology 10, 1856, 2019 | 114* | 2019 |
| The same self-peptide selects conventional and regulatory CD4+ T cells with identical antigen receptors L Wojciech, A Ignatowicz, M Seweryn, G Rempala, S Singh Pabla, ... Nature communications 5 (1), 5061, 2014 | 31 | 2014 |
| Cytokeratin-8 in anaplastic thyroid carcinoma: More than a simple structural cytoskeletal protein D Guo, Q Xu, S Pabla, J Koomen, P Biddinger, A Sharma, S Pabla, ... International journal of molecular sciences 19 (2), 577, 2018 | 25 | 2018 |
| Real-time polymerase chain reaction: A revolution in diagnostics SS Pabla, SS Pabla Resonance 13, 369-377, 2008 | 13 | 2008 |
| Engineering CD70-directed CAR-NK cells for the treatment of hematological and solid malignancies E Choi, JW Chang, J Krueger, WS Lahr, E Pomeroy, M Walsh, ... Blood 138, 1691, 2021 | 12 | 2021 |
| Expanding the therapeutic potential of anti-PD-1 and anti-CTLA-4 therapy with innovative Fc engineering and rationale combinations for the treatment of solid tumors A Tanne, S Vincent, E Paltrinieri, S Pawaria, V Patel, M Marilyn, ... Cancer Res 80 (16 Suppl), 2020 | 1 | 2020 |
| Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies JW Chang, J Kreuger, J Skeate, E Stelljes, W Lahr, N Slipek, E Pomeroy, ... Journal for ImmunoTherapy of Cancer 10, A413-A413, 2022 | | 2022 |
| Engineered Allogeneic CAR Natural Killer Cells Resist Tumor Microenvironment Immunosuppression by Expression of TGFBR2 Dominant Negative Receptor J Johnson, JA Storer, M Walsh, S Pabla, J Sewell, F Moore, L Barron, ... MOLECULAR THERAPY 30 (4), 150-151, 2022 | | 2022 |
| Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimab I Shapiro, M Lim, S Pabla, S O’Day, A El-Khoueiry, C Ramamurthy, ... Cancer Research 81 (13), 2021 | | 2021 |
| 70 Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro S Pabla, T Khendu, D Chand, B Aksoy, B Duckless, A Basinski, C Joyce, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | | 2020 |
| Driving T cell dysfunction in vitro for rational immunotherapy design M Hancock, C Joyce, T Horn, S Pabla, B Duckless, A Basinski, D Chand, ... | | 2019 |
| A novel subnetwork based analysis reveals shared pathways in T-cell mediated autoimmunity SS Pabla Augusta University, 2016 | | 2016 |
| SUMOylation Site Prediction using Support Vector Machines SS Pabla, SS Pabla, H Panchal Journal of Computational Intelligence in Bioinformatics 2 (2), 103-107, 2009 | | 2009 |
| P291 CE Joyce, M Hancock, T Horn, S Pabla, B Duckless, A Basinski, D Chand, ... Gene expression [log2] 13, 11, 0 | | |
| Using Big Data and Machine Learning to Understand T cell Dysfunction in Human Tumors S Pabla, T Khendu, C Joyce, B Duckless, A Basinski, M Hancock, ... Gene expression [log2] 13, 11, 0 | | |
| PROLYZER: A wireless application for Physico-chemical analysis of protein sequences SS Pabla, SS Pabla, PS Sajja | | |
Pawel KisielowVerified email at iitd.pan.wroc.pl
